Viracta Therapeutics Inc represents a commitment to innovation and advancing the field of cancer treatment. With a focus on developing targeted therapies for viral-associated cancers, the company aims to provide effective and personalized treatment options. Guided by a patient-centric approach, Viracta Therapeutics Inc prioritizes collaboration and scientific excellence to deliver groundbreaking therapies. The company's dedication to improving patient outcomes is fueled by cutting-edge research, strategic partnerships, and a relentless pursuit of scientific discovery. With its mission to transform the lives of patients, Viracta Therapeutics Inc embodies a culture of integrity, compassion, and the pursuit of excellence in the fight against cancer.

Viracta Therapeutics Inc is primarily present in the United States.

Viracta Therapeutics Inc has achieved several significant milestones in its journey. Notably, the company successfully completed a Phase 1b/2 clinical trial evaluating its lead product candidate, nanatinostat, in combination with valganciclovir, for the treatment of Epstein-Barr virus (EBV)-associated lymphomas and solid tumors. The trial demonstrated promising results, including a high overall response rate and durable responses in patients with EBV-positive lymphomas. Additionally, Viracta Therapeutics received Fast Track designation from the U.S. FDA for nanatinostat in combination with valganciclovir, highlighting the potential of this therapy to address unmet medical needs. These achievements signify Viracta's commitment towards finding innovative solutions for patients with EBV-associated cancers.

Viracta Therapeutics Inc is a clinical-stage biotechnology company founded in 2015. The company is focused on developing innovative targeted therapies for the treatment of virus-associated cancers. Viracta's proprietary investigational drug, nanatinostat (VRx-3996), is being evaluated in combination with valganciclovir as a potential treatment for Epstein-Barr virus (EBV)-associated lymphomas and solid tumors. By targeting the viral cause of the cancer, Viracta Therapeutics aims to provide a novel approach to treating these difficult-to-treat malignancies. With its commitment to advancing precision medicine, Viracta Therapeutics Inc is poised to make a significant impact in the field of oncology.

The main competitors of Viracta Therapeutics Inc in the market include companies such as Gilead Sciences Inc, Merck & Co. Inc, and Bristol-Myers Squibb Company.

Viracta Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on developing innovative therapies for the treatment of viral-related cancers, Viracta Therapeutics Inc is committed to revolutionizing healthcare through cutting-edge research and drug development. By harnessing the power of virus-targeted anti-cancer therapies, the company aims to make significant advancements in oncology treatment and improve patient outcomes. As a leader in the field, Viracta Therapeutics Inc continues to drive advancements in viral oncology, paving the way for new and improved therapeutic options for cancer patients.

The business model of Viracta Therapeutics Inc is focused on developing targeted antiviral therapies for the treatment of patients with virus-associated cancers. Viracta utilizes its proprietary synthetic lethality approach to design and develop small molecule drugs that selectively kill virus-infected cells, while sparing normal cells. The company aims to address the unmet medical needs of patients with virus-associated cancers by providing innovative therapeutics that specifically target the underlying viral infection. Through its research and development efforts, Viracta aims to improve patient outcomes and offer a novel approach to treating virus-associated cancers.

P/E odnos Viracta Therapeutics iznosi -0,26.

KUV kompanije Viracta Therapeutics iznosi 0.

AlleAktien kvalitativni skor za Viracta Therapeutics je 3/10.

Prihod trenutno ne može biti izračunat za Viracta Therapeutics.

Dobit očekivana Viracta Therapeutics je -34,98 mil. USD.

Viracta Therapeutics Inc. is a biopharmaceutical company focused on therapeutics for the treatment of virus-associated cancers. The company's business model is based on identifying and developing drugs to combat cancers caused by viruses, particularly those caused by the Epstein-Barr virus (EBV). Viracta's business model includes three core areas: research, development, and marketing of therapeutics. The company works closely with academic institutions and other biotech companies to support its research efforts. Viracta utilizes its proprietary platform technology to understand the molecular mechanisms of virus-associated cancers. Based on this platform, the company identifies potential molecules that can specifically target viruses to destroy cancer cells. These molecules undergo extensive preclinical testing before moving into clinical development. Viracta has already begun the clinical development process for its leading therapeutic platform called "Nanatinostat," which aims to treat certain cancers caused by EBV. Nanatinostat is a combination of a histone deacetylase inhibitor (HDACi) and valproic acid. The Nanatinostat platform is used to treat lymphomas and other cancers caused by EBV. Viracta plans to test the platform in combination with other drugs such as rituximab and pembrolizumab to enhance efficacy. Viracta has also partnered with the Republic of China (Taiwan) to accelerate the discovery and development of HDAC inhibitors for the treatment of virus-associated cancers. This partnership is a significant milestone for the company as it provides access to a range of resources and funding opportunities to support its research and product development activities. In addition to its research and development activities, Viracta collaborates closely with pharmaceutical and biotech companies to market and distribute its products and technologies. The company leverages its extensive networks to promote its products and strengthen its brand. Overall, Viracta's business model is focused on developing therapeutics for virus-associated cancers. The company utilizes its proprietary platform technology to identify molecules that specifically target viruses to destroy cancer cells. Currently, Nanatinostat is the leading platform being used to treat lymphomas and other EBV-associated cancers. With its extensive partnerships and networks, Viracta is well-positioned to promote its products and technologies and facilitate access to funding opportunities.

Viracta Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Viracta Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Viracta Therapeutics je US92765F1084.

WKN od Viracta Therapeutics je A2QQRS.

Oznaka za praćenje akcija kompanije Viracta Therapeutics je VIRX.

U poslednjih 12 meseci, Viracta Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Viracta Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Viracta Therapeutics trenutno iznosi .

Viracta Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Viracta Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Viracta Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Viracta Therapeutics od 3. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 3. 10. 2024..

Isplata poslednje dividende izvršena je 3. 10. 2024..

U godini 2023 kompanija Viracta Therapeutics je isplatila 0 USD kao dividende.

Dividende od Viracta Therapeutics se isplaćuju u USD.